Endothelin receptor antagonists: Potential in Alzheimer's disease

Alzheimer's disease (AD) is believed to be initiated by the accumulation of neurotoxic forms of A beta peptide within the brain. AD patients show reduction of cerebral blood flow (CBF), the extent of the reduction correlating with the impairment of cognition. There is evidence that cerebral hypoperfusion precedes and may even trigger the onset of dementia in AD. Cerebral hypoperfusion impairs neuronal function, reduces the clearance of A beta peptide and other toxic metabolites from the brain, and upregulates A beta production. Studies in animal models of AD have shown the reduction in CBF to be more than would be expected for the reduction in neuronal metabolic activity. A beta may contribute to the reduction in CBF in AD, as both A beta(1-40) and A beta(1-42) induce cerebrovascular dysfunction. A beta(1-40) acts directly on cerebral arteries to cause cerebral smooth muscle cell contraction. A beta(1-42) causes increased neuronal production and release of endothelin-1 (ET-1), a potent vasoconstrictor, and upregulation of endothelin-converting enzyme-2 (ECE-2), the enzyme which cleaves ET-1 from its inactive precursor. ET-1 and ECE-2 are also elevated in AD, making it likely that upregulation of the ECE-2-ET-1 axis by A beta(1-42) contributes to the chronic reduction of CBF in AD. At present, only a few symptomatic treatment options exist for AD. The involvement of ET-1 in the pathogenesis of endothelial dysfunction associated with elevated A beta indicates the potential for endothelin receptor antagonists in the treatment of AD. It has already been demonstrated that the endothelin receptor antagonist bosentan, preserves aortic and carotid endothelial function in Tg2576 mice, and our findings suggest that endothelin receptor antagonists may be beneficial in maintaining CBF in AD. (C) 2011 Elsevier Ltd. All rights reserved.